SNDX
−$22.4K
1,177 sh @ $19
SNDX
Syndax Pharmaceuticals Inc
SEC CIK 1395937
$17.91
−15.7% · 90 days
90-day buys
$0
0 open-market
90-day sells
$152.4K
2 open-market
Net insider flow
−$152.4K
Net selling
Filings shown
38
Most recent
At a glance
Over the last 90 days, insiders at SNDX have sold a net $152.4K of stock (0 open-market buys vs 2 sells).
Largest recent trade: Metzger Michael A sold $2.58M of SNDX, trimming their stake 34%.
Most active filer: Metzger Michael A, with 11 transactions among the recent filings shown.
Insider transaction history
Form 4 filings for SNDX, newest firstSNDX
−$130K
6,847 sh @ $19
SNDX
−$360.8K
17,159 sh @ $21
SNDX
−$71.7K
3,410 sh @ $21
SNDX
−$152.8K
7,412 sh @ $21
SNDX
−$42.9K
2,082 sh @ $21
SNDX
+$0
73,000 sh
SNDX
+$0
144,600 sh
SNDX
+$0
21,500 sh
SNDX
+$0
30,750 sh
SNDX
+$0
24,000 sh
SNDX
+$0
24,000 sh
SNDX
+$0
24,000 sh
SNDX
+$0
36,000 sh
SNDX
+$0
48,000 sh
SNDX
+$0
24,000 sh
SNDX
+$0
24,000 sh
SNDX
+$0
24,000 sh
SNDX
+$10.3K
1,219 sh @ $8
SNDX
−$0
1,224 sh
SNDX
+$1.71M
157,307 sh @ $11
SNDX
−$2.58M
157,307 sh @ $16
SNDX
+$138.2K
19,200 sh @ $7
SNDX
−$304.2K
19,200 sh @ $16
SNDX
+$138.2K
19,200 sh @ $7
SNDX
−$298.4K
19,200 sh @ $16
SNDX
+$138.2K
19,200 sh @ $7
SNDX
−$272.5K
19,200 sh @ $14
SNDX
+$10.3K
1,226 sh @ $8
SNDX
−$12K
1,296 sh @ $9
SNDX
−$70K
7,534 sh @ $9
SNDX
Goldan Keith A., SNDX's CFO, spent $0 of their own money on 3,000 shares, growing their stake 3%.
+$0
3,000 sh
SNDX
Huber Martin H. Jr., SNDX's Director, spent $45K of their own money on 5,000 shares at $9, growing their stake 7%.
+$45K
5,000 sh @ $9
SNDX
Katkin Keith, SNDX's Director, spent $91.1K of their own money on 10,000 shares at $9, growing their stake 11%.
+$91.1K
10,000 sh @ $9
SNDX
Botwood Nicholas A.j., SNDX's Head of R&D, spent $105.8K of their own money on 11,765 shares at $9, growing their stake 50%.
+$105.8K
11,765 sh @ $9
SNDX
+$43.7K
6,074 sh @ $7
SNDX
+$56.3K
7,814 sh @ $7
SNDX
−$117.6K
7,814 sh @ $15
About SNDX insider activity
This page tracks every recent Form 4 filed for Syndax Pharmaceuticals Inc with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.
The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.
Frequently asked questions
How often is SNDX insider data updated?
Continuously. We read from SEC EDGAR, so new Form 4 filings for Syndax Pharmaceuticals Inc usually appear here within minutes of being accepted by the SEC.
What does "net insider flow" mean?
It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.
Why do some rows show grants or option exercises instead of buys?
Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.
Is this investment advice?
No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.